Expertise in
10
conditions

Dr. Steven I. Park

Internal Medicine
Steven K. Park M. D. P.A.
330 Route 45 Ste 3, 
Salem, NJ 
Expertise in
10
conditions
Steven K. Park M. D. P.A.
330 Route 45 Ste 3, 
Salem, NJ 

Overview

Steven Park is a primary care provider, practicing in Internal Medicine in Salem, New Jersey.

Dr. Park is highly rated in 10 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Mantle Cell Lymphoma (MCL), B-Cell Lymphoma, and Diffuse Large B-Cell Lymphoma (DLBCL).

He is actively involved in clinical research, co-authoring 62 peer reviewed articles and participating in 18 clinical trials.

Specialties

Internal Medicine

Licenses

Internal Medicine in NJ

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

Steven K. Park M. D. P.A.
330 Route 45 Ste 3, Salem, NJ 08079

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

16 Clinical Trials

Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs. RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma
Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs. RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Drug, Biological, Other
Study Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Lenalidomide, Prednisone, Rituximab, Vincristine Sulfate
Study Phase: Phase 2
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: August 10, 2026
Intervention Type: Combination product, Drug
Study Drugs: Tazemetostat, Lenalidomide, Rituximab
Study Phase: Phase 3
Phase Ib/II Study of the Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Relapsed/Refractory CD30+ Hodgkin's Lymphoma and CD30+ Non-Hodgkin's Lymphoma
Phase Ib/II Study of the Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Relapsed/Refractory CD30+ Hodgkin's Lymphoma and CD30+ Non-Hodgkin's Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: July 07, 2026
Intervention Type: Biological
Study Drug: ATLCAR.CD30 cells
Study Phase: Phase 1/Phase 2
Phase I Study of the Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Prevention of Relapse of CD30+ Lymphomas After High Dose Therapy and Autologous Stem Transplantation (ATLAS)
Phase I Study of the Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Prevention of Relapse of CD30+ Lymphomas After High Dose Therapy and Autologous Stem Transplantation (ATLAS)
Enrollment Status: Active_not_recruiting
Publish Date: June 09, 2026
Intervention Type: Drug
Study Drug: Anti-CD30 CAR-T Cells
Study Phase: Phase 1
A Phase I Trial of Ibrutinib Plus PD 0332991 (Palbociclib) in Patients With Previously Treated Mantle Cell Lymphoma
A Phase I Trial of Ibrutinib Plus PD 0332991 (Palbociclib) in Patients With Previously Treated Mantle Cell Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: May 27, 2026
Intervention Type: Drug, Other
Study Drugs: Ibrutinib, Palbociclib
Study Phase: Phase 1
A Phase 1B Trial Nivolumab Consolidation Following Completion of High-Dose Methotrexate Containing Induction Chemotherapy in Older (≥ 65) Patients With Primary CNS Lymphoma
A Phase 1B Trial Nivolumab Consolidation Following Completion of High-Dose Methotrexate Containing Induction Chemotherapy in Older (≥ 65) Patients With Primary CNS Lymphoma
Enrollment Status: Completed
Publish Date: December 30, 2025
Intervention Type: Drug
Study Phase: Phase 1
A Phase II Trial of PET-Directed Therapy Using AVD (Doxorubicin, Vinblastine, and Dacarbazine) Plus Brentuximab Vedotin Induction Chemotherapy, With or Without Brentuximab Vedotin Plus Nivolumab, Followed by Nivolumab Consolidation for Patients With Previously Untreated Non-Bulky Limited Stage Hodgkin Lymphoma
A Phase II Trial of PET-Directed Therapy Using AVD (Doxorubicin, Vinblastine, and Dacarbazine) Plus Brentuximab Vedotin Induction Chemotherapy, With or Without Brentuximab Vedotin Plus Nivolumab, Followed by Nivolumab Consolidation for Patients With Previously Untreated Non-Bulky Limited Stage Hodgkin Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: October 03, 2025
Intervention Type: Drug, Biological, Other
Study Drugs: Brentuximab, Dacarbazine, Doxorubicin, Nivolumab, Vinblastine
Study Phase: Phase 2
A Multi-Center, Phase 2, Open-label, Parallel Cohort Study of Efficacy and Safety of Duvelisib in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
A Multi-Center, Phase 2, Open-label, Parallel Cohort Study of Efficacy and Safety of Duvelisib in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Enrollment Status: Completed
Publish Date: March 07, 2025
Intervention Type: Drug
Study Drug: Duvelisib
Study Phase: Phase 2
A Phase 2 Front-Line PET/CT-2 Response-Adapted Brentuximab Vedotin and Nivolumab Incorporated and Radiation-Free Management of Early Stage Classical Hodgkin Lymphoma (cHL)
A Phase 2 Front-Line PET/CT-2 Response-Adapted Brentuximab Vedotin and Nivolumab Incorporated and Radiation-Free Management of Early Stage Classical Hodgkin Lymphoma (cHL)
Enrollment Status: Active_not_recruiting
Publish Date: November 06, 2024
Intervention Type: Other, Drug, Biological
Study Drugs: Bleomycin, Brentuximab, Dacarbazine, Doxorubicin, Nivolumab, Vinblastine
Study Phase: Phase 2
Phase 1/2 Study of TAK-981 in Combination With Rituximab in Patients With Relapsed/Refractory CD20-Positive Non-Hodgkin Lymphoma
Phase 1/2 Study of TAK-981 in Combination With Rituximab in Patients With Relapsed/Refractory CD20-Positive Non-Hodgkin Lymphoma
Enrollment Status: Terminated
Publish Date: June 14, 2024
Intervention Type: Drug
Study Drugs: TAK-981, Rituximab
Study Phase: Phase 1/Phase 2
View 9 Less Clinical Trials

62 Total Publications

Outcomes From the Multicenter ACCRU-LY-1804/CARiBOU TRIAL (Cytarabine, Acalabrutinib and Rituximab Integrated With Bortezomib-Based Outpatient Therapy) in 1st Line Mantle Cell Lymphoma.
Outcomes From the Multicenter ACCRU-LY-1804/CARiBOU TRIAL (Cytarabine, Acalabrutinib and Rituximab Integrated With Bortezomib-Based Outpatient Therapy) in 1st Line Mantle Cell Lymphoma.
Journal: American journal of hematology
Published: March 25, 2026
Similar Doctors
Expertise in
20
conditions
Dr. Henry P. Parkman
Internal Medicine
Expertise in
20
conditions
Dr. Henry P. Parkman
Internal Medicine

Temple University Hospital

3401 N Broad St, 
Philadelphia, PA 
 (35.3 miles away)
215-707-9900
Experience:
44+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Henry Parkman is a primary care provider, practicing in Internal Medicine in Philadelphia, Pennsylvania. He has been practicing medicine for over 44 years. Dr. Parkman is highly rated in 20 conditions, according to our data. His clinical expertise encompasses Gastroparesis, Gastroesophageal Reflux Disease (GERD), Gastric Dysmotility, Endoscopy, and Lung Transplant. Dr. Parkman is currently accepting new patients.

Expertise in
24
conditions
Dr. Aditi P. Sinha
Internal Medicine
Expertise in
24
conditions
Dr. Aditi P. Sinha
Internal Medicine

Bayhealth Hospital Kent Campus

640 S State St, 
Dover, DE 
 (27.5 miles away)
302-744-7581
Languages Spoken:
English
See accepted insurances

Aditi Sinha is a primary care provider, practicing in Internal Medicine in Dover, Delaware. Dr. Sinha is highly rated in 24 conditions, according to our data. Her clinical expertise encompasses Nephrotic Syndrome, D-Minus Hemolytic Uremic Syndrome, D-Plus Hemolytic Uremic Syndrome, Kidney Transplant, and Tenotomy.

Expertise in
18
conditions
Dr. David C. Metz
Internal Medicine
Expertise in
18
conditions
Dr. David C. Metz
Internal Medicine

Penn Endocrine And Oncologic Surgery Perelman 3RD Floor

3400 Civic Center Blvd Fl 4, 
Philadelphia, PA 
 (31.3 miles away)
800-789-7366
Languages Spoken:
English
See accepted insurances

David Metz is a primary care provider, practicing in Internal Medicine in Philadelphia, Pennsylvania. Dr. Metz is highly rated in 18 conditions, according to our data. His clinical expertise encompasses Neuroendocrine Tumor, Zollinger-Ellison Syndrome, Pancreatic Islet Cell Tumor, Endoscopy, and Colonoscopy.

Frequently Asked Questions about Dr. Steven I. Park

How do I make an appointment with Dr. Steven I. Park?

You can book an appointment with Dr. Steven I. Park by calling their office at 856-935-7757. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Steven I. Park a top-rated expert for Non-Hodgkin Lymphoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Steven I. Park is classified as an Elite expert for Non-Hodgkin Lymphoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Steven I. Park specialize in?

While Dr. Steven I. Park is a Internal Medicine, they have specific expertise in Non-Hodgkin Lymphoma, Mantle Cell Lymphoma (MCL), and B-Cell Lymphoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Internal Medicine.

Does Dr. Steven I. Park participate in research or clinical trials?

Yes. Dr. Steven I. Park has published 62 articles and abstracts on conditions like Non-Hodgkin Lymphoma. You can view a list of Dr. Steven I. Park's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Park's expertise for a condition
ConditionClose
View All 23 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile